#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Over the last few decades , accumulating evidence has demonstrated that numerous Interferon ( IFN ) stimulate genes ( ISGs ) can be directly upregulated following virus infection independent of IFN signaling .
1-1	0-4	Over	_	_	_	_
1-2	5-8	the	time[1]	new[1]	_	_
1-3	9-13	last	time[1]	new[1]	_	_
1-4	14-17	few	time[1]	new[1]	_	_
1-5	18-25	decades	time[1]	new[1]	_	_
1-6	26-27	,	_	_	_	_
1-7	28-40	accumulating	_	_	_	_
1-8	41-49	evidence	abstract	new	_	_
1-9	50-53	has	_	_	_	_
1-10	54-66	demonstrated	_	_	_	_
1-11	67-71	that	_	_	_	_
1-12	72-80	numerous	organization[3]	new[3]	coref	15-58[0_3]
1-13	81-91	Interferon	organization[3]	new[3]	_	_
1-14	92-93	(	_	_	_	_
1-15	94-97	IFN	abstract	new	coref	1-31
1-16	98-99	)	_	_	_	_
1-17	100-109	stimulate	_	_	_	_
1-18	110-115	genes	abstract	new	appos	1-20
1-19	116-117	(	_	_	_	_
1-20	118-122	ISGs	abstract	giv	coref	2-12[14_0]
1-21	123-124	)	_	_	_	_
1-22	125-128	can	_	_	_	_
1-23	129-131	be	_	_	_	_
1-24	132-140	directly	_	_	_	_
1-25	141-152	upregulated	_	_	_	_
1-26	153-162	following	_	_	_	_
1-27	163-168	virus	abstract|event[8]	new|new[8]	coref|coref|coref|coref	3-6|8-16[54_8]|3-6|8-16[54_8]
1-28	169-178	infection	event[8]	new[8]	_	_
1-29	179-190	independent	event[8]	new[8]	_	_
1-30	191-193	of	_	_	_	_
1-31	194-197	IFN	abstract|abstract[10]	giv|new[10]	coref|coref|coref|coref	2-9[13_10]|16-47[172_0]|2-9[13_10]|16-47[172_0]
1-32	198-207	signaling	abstract[10]	new[10]	_	_
1-33	208-209	.	_	_	_	_

#Text=Indeed , whereas typical ISGs are driven by JAK-STAT signaling , other virally-stimulated genes are upregulated through the IRF3 and NF-κB pathways .
2-1	210-216	Indeed	_	_	_	_
2-2	217-218	,	_	_	_	_
2-3	219-226	whereas	_	_	_	_
2-4	227-234	typical	abstract[11]	new[11]	_	_
2-5	235-239	ISGs	abstract[11]	new[11]	_	_
2-6	240-243	are	_	_	_	_
2-7	244-250	driven	_	_	_	_
2-8	251-253	by	_	_	_	_
2-9	254-262	JAK-STAT	abstract|abstract[13]	new|giv[13]	_	_
2-10	263-272	signaling	abstract[13]	giv[13]	_	_
2-11	273-274	,	_	_	_	_
2-12	275-280	other	abstract[14]	giv[14]	coref	3-1[17_14]
2-13	281-299	virally-stimulated	abstract[14]	giv[14]	_	_
2-14	300-305	genes	abstract[14]	giv[14]	_	_
2-15	306-309	are	_	_	_	_
2-16	310-321	upregulated	_	_	_	_
2-17	322-329	through	_	_	_	_
2-18	330-333	the	abstract[15]	new[15]	coref	18-5[0_15]
2-19	334-338	IRF3	abstract[15]	new[15]	_	_
2-20	339-342	and	_	_	_	_
2-21	343-348	NF-κB	place[16]	new[16]	coref	10-26[80_16]
2-22	349-357	pathways	place[16]	new[16]	_	_
2-23	358-359	.	_	_	_	_

#Text=These genes can be called virus stimulated genes ( VSGs ) , and IFNs themselves are VSGs .
3-1	360-365	These	abstract[17]	giv[17]	coref	3-6[19_17]
3-2	366-371	genes	abstract[17]	giv[17]	_	_
3-3	372-375	can	_	_	_	_
3-4	376-378	be	_	_	_	_
3-5	379-385	called	_	_	_	_
3-6	386-391	virus	abstract|abstract[19]	giv|giv[19]	appos|coref|appos|coref	3-10[0_19]|8-16|3-10[0_19]|8-16
3-7	392-402	stimulated	abstract[19]	giv[19]	_	_
3-8	403-408	genes	abstract[19]	giv[19]	_	_
3-9	409-410	(	_	_	_	_
3-10	411-415	VSGs	abstract	giv	ana	3-15
3-11	416-417	)	_	_	_	_
3-12	418-419	,	_	_	_	_
3-13	420-423	and	_	_	_	_
3-14	424-428	IFNs	abstract[21]	new[21]	_	_
3-15	429-439	themselves	abstract[21]|abstract	new[21]|giv	coref	3-17
3-16	440-443	are	_	_	_	_
3-17	444-448	VSGs	abstract	giv	coref	4-3
3-18	449-450	.	_	_	_	_

#Text=Interestingly , VSGs have natural anticancer activities , and they may cause diseases in humans when induced chronically .
4-1	451-464	Interestingly	_	_	_	_
4-2	465-466	,	_	_	_	_
4-3	467-471	VSGs	abstract	giv	coref	6-12
4-4	472-476	have	_	_	_	_
4-5	477-484	natural	abstract[26]	new[26]	ana	4-10[0_26]
4-6	485-495	anticancer	abstract|abstract[26]	new|new[26]	_	_
4-7	496-506	activities	abstract[26]	new[26]	_	_
4-8	507-508	,	_	_	_	_
4-9	509-512	and	_	_	_	_
4-10	513-517	they	abstract	giv	coref	21-18[232_0]
4-11	518-521	may	_	_	_	_
4-12	522-527	cause	_	_	_	_
4-13	528-536	diseases	abstract	new	_	_
4-14	537-539	in	_	_	_	_
4-15	540-546	humans	person	new	ana	5-3
4-16	547-551	when	_	_	_	_
4-17	552-559	induced	_	_	_	_
4-18	560-571	chronically	_	_	_	_
4-19	572-573	.	_	_	_	_

#Text=To understand their role in host defense and pathogenesis , excellent model systems have been developed .
5-1	574-576	To	_	_	_	_
5-2	577-587	understand	abstract|abstract	new|new	coref|coref|none|none|coref|coref|none|none	6-9[39_0]|20-6[219_0]|5-2[0_39]|5-2[0_219]|6-9[39_0]|20-6[219_0]|5-2[0_39]|5-2[0_219]
5-3	588-593	their	person|abstract[31]	giv|new[31]	coref|coref	8-19[55_31]|8-19[55_31]
5-4	594-598	role	abstract[31]	new[31]	_	_
5-5	599-601	in	abstract[31]	new[31]	_	_
5-6	602-606	host	abstract[31]|person|abstract[33]	new[31]|new|new[33]	coref|coref|coref|coref	6-15[0_33]|10-27|6-15[0_33]|10-27
5-7	607-614	defense	abstract[31]|abstract[33]	new[31]|new[33]	_	_
5-8	615-618	and	abstract[31]	new[31]	_	_
5-9	619-631	pathogenesis	abstract[31]|abstract	new[31]|new	_	_
5-10	632-633	,	_	_	_	_
5-11	634-643	excellent	abstract[36]	new[36]	_	_
5-12	644-649	model	abstract|abstract[36]	new|new[36]	_	_
5-13	650-657	systems	abstract[36]	new[36]	_	_
5-14	658-662	have	_	_	_	_
5-15	663-667	been	_	_	_	_
5-16	668-677	developed	_	_	_	_
5-17	678-679	.	_	_	_	_

#Text=However , there are still important gaps in our understanding of VSGs and host defense .
6-1	680-687	However	_	_	_	_
6-2	688-689	,	_	_	_	_
6-3	690-695	there	_	_	_	_
6-4	696-699	are	_	_	_	_
6-5	700-705	still	abstract[37]	new[37]	_	_
6-6	706-715	important	abstract[37]	new[37]	_	_
6-7	716-720	gaps	abstract[37]	new[37]	_	_
6-8	721-723	in	abstract[37]	new[37]	_	_
6-9	724-727	our	abstract[37]|person|abstract[39]	new[37]|acc|new[39]	ana|ana	9-1|9-1
6-10	728-741	understanding	abstract[37]|abstract[39]	new[37]|new[39]	_	_
6-11	742-744	of	abstract[37]|abstract[39]	new[37]|new[39]	_	_
6-12	745-749	VSGs	abstract[37]|abstract[39]|abstract	new[37]|new[39]|giv	coref	7-11[46_0]
6-13	750-753	and	_	_	_	_
6-14	754-758	host	_	_	_	_
6-15	759-766	defense	abstract	giv	coref	10-28
6-16	767-768	.	_	_	_	_

#Text=Recently , RNA sequencing techniques have allowed the discovery of novel VSGs that also include non-coding RNAs .
7-1	769-777	Recently	_	_	_	_
7-2	778-779	,	_	_	_	_
7-3	780-783	RNA	substance|abstract[44]	new|new[44]	_	_
7-4	784-794	sequencing	abstract|abstract[44]	new|new[44]	_	_
7-5	795-805	techniques	abstract[44]	new[44]	_	_
7-6	806-810	have	_	_	_	_
7-7	811-818	allowed	_	_	_	_
7-8	819-822	the	event[45]	new[45]	_	_
7-9	823-832	discovery	event[45]	new[45]	_	_
7-10	833-835	of	event[45]	new[45]	_	_
7-11	836-841	novel	event[45]|abstract[46]	new[45]|giv[46]	coref	8-11[0_46]
7-12	842-846	VSGs	event[45]|abstract[46]	new[45]|giv[46]	_	_
7-13	847-851	that	_	_	_	_
7-14	852-856	also	_	_	_	_
7-15	857-864	include	_	_	_	_
7-16	865-875	non-coding	abstract[47]	new[47]	_	_
7-17	876-880	RNAs	abstract[47]	new[47]	_	_
7-18	881-882	.	_	_	_	_

#Text=This Special Issue of Viruses will explore the impact of VSGs on the outcome of virus infection and the role of these genes within the infected cells and organism .
8-1	883-887	This	abstract[48]	new[48]	coref	12-2[88_48]
8-2	888-895	Special	abstract[48]	new[48]	_	_
8-3	896-901	Issue	abstract[48]	new[48]	_	_
8-4	902-904	of	abstract[48]	new[48]	_	_
8-5	905-912	Viruses	abstract[48]|abstract	new[48]|new	_	_
8-6	913-917	will	_	_	_	_
8-7	918-925	explore	_	_	_	_
8-8	926-929	the	abstract[50]	new[50]	_	_
8-9	930-936	impact	abstract[50]	new[50]	_	_
8-10	937-939	of	abstract[50]	new[50]	_	_
8-11	940-944	VSGs	abstract[50]|abstract	new[50]|giv	coref	8-22[56_0]
8-12	945-947	on	abstract[50]	new[50]	_	_
8-13	948-951	the	abstract[50]|abstract[52]	new[50]|new[52]	_	_
8-14	952-959	outcome	abstract[50]|abstract[52]	new[50]|new[52]	_	_
8-15	960-962	of	abstract[50]|abstract[52]	new[50]|new[52]	_	_
8-16	963-968	virus	abstract[50]|abstract[52]|abstract|event[54]	new[50]|new[52]|giv|giv[54]	coref|coref|coref|coref	9-18[64_0]|10-15[74_54]|9-18[64_0]|10-15[74_54]
8-17	969-978	infection	abstract[50]|abstract[52]|event[54]	new[50]|new[52]|giv[54]	_	_
8-18	979-982	and	abstract[50]|abstract[52]	new[50]|new[52]	_	_
8-19	983-986	the	abstract[50]|abstract[52]|abstract[55]	new[50]|new[52]|giv[55]	_	_
8-20	987-991	role	abstract[50]|abstract[52]|abstract[55]	new[50]|new[52]|giv[55]	_	_
8-21	992-994	of	abstract[50]|abstract[52]|abstract[55]	new[50]|new[52]|giv[55]	_	_
8-22	995-1000	these	abstract[50]|abstract[52]|abstract[55]|abstract[56]	new[50]|new[52]|giv[55]|giv[56]	coref	11-11[0_56]
8-23	1001-1006	genes	abstract[50]|abstract[52]|abstract[55]|abstract[56]	new[50]|new[52]|giv[55]|giv[56]	_	_
8-24	1007-1013	within	abstract[50]|abstract[52]|abstract[55]|abstract[56]	new[50]|new[52]|giv[55]|giv[56]	_	_
8-25	1014-1017	the	abstract[50]|abstract[52]|abstract[55]|abstract[56]|object[57]	new[50]|new[52]|giv[55]|giv[56]|new[57]	coref	16-34[0_57]
8-26	1018-1026	infected	abstract[50]|abstract[52]|abstract[55]|abstract[56]|object[57]	new[50]|new[52]|giv[55]|giv[56]|new[57]	_	_
8-27	1027-1032	cells	abstract[50]|abstract[52]|abstract[55]|abstract[56]|object[57]	new[50]|new[52]|giv[55]|giv[56]|new[57]	_	_
8-28	1033-1036	and	abstract[50]|abstract[52]|abstract[55]|abstract[56]	new[50]|new[52]|giv[55]|giv[56]	_	_
8-29	1037-1045	organism	abstract[50]|abstract[52]|abstract[55]|abstract[56]|abstract	new[50]|new[52]|giv[55]|giv[56]|new	_	_
8-30	1046-1047	.	_	_	_	_

#Text=We have focused on the most recent discoveries in VSG research , including the molecular biology of related virus – host interactions .
9-1	1048-1050	We	person	giv	ana	12-6
9-2	1051-1055	have	_	_	_	_
9-3	1056-1063	focused	_	_	_	_
9-4	1064-1066	on	_	_	_	_
9-5	1067-1070	the	abstract[60]	new[60]	_	_
9-6	1071-1075	most	abstract[60]	new[60]	_	_
9-7	1076-1082	recent	abstract[60]	new[60]	_	_
9-8	1083-1094	discoveries	abstract[60]	new[60]	_	_
9-9	1095-1097	in	abstract[60]	new[60]	_	_
9-10	1098-1101	VSG	abstract[60]|abstract|abstract[62]	new[60]|new|new[62]	coref|coref	12-30[0_62]|12-30[0_62]
9-11	1102-1110	research	abstract[60]|abstract[62]	new[60]|new[62]	_	_
9-12	1111-1112	,	_	_	_	_
9-13	1113-1122	including	_	_	_	_
9-14	1123-1126	the	abstract[63]	new[63]	_	_
9-15	1127-1136	molecular	abstract[63]	new[63]	_	_
9-16	1137-1144	biology	abstract[63]	new[63]	_	_
9-17	1145-1147	of	abstract[63]	new[63]	_	_
9-18	1148-1155	related	abstract[63]|abstract[64]	new[63]|giv[64]	coref	10-15[0_64]
9-19	1156-1161	virus	abstract[63]|abstract[64]	new[63]|giv[64]	_	_
9-20	1162-1163	–	_	_	_	_
9-21	1164-1168	host	_	_	_	_
9-22	1169-1181	interactions	abstract	new	_	_
9-23	1182-1183	.	_	_	_	_

#Text=Topics include studies on various steps of gene induction , innate immune responses to virus infection , and the mechanisms of virus immune evasion of related host defense pathways .
10-1	1184-1190	Topics	abstract	new	_	_
10-2	1191-1198	include	_	_	_	_
10-3	1199-1206	studies	event	new	_	_
10-4	1207-1209	on	_	_	_	_
10-5	1210-1217	various	abstract[68]	new[68]	_	_
10-6	1218-1223	steps	abstract[68]	new[68]	_	_
10-7	1224-1226	of	abstract[68]	new[68]	_	_
10-8	1227-1231	gene	abstract[68]|abstract|abstract[70]	new[68]|new|new[70]	_	_
10-9	1232-1241	induction	abstract[68]|abstract[70]	new[68]|new[70]	_	_
10-10	1242-1243	,	abstract[68]	new[68]	_	_
10-11	1244-1250	innate	abstract[68]|abstract[72]	new[68]|new[72]	coref	15-16[143_72]
10-12	1251-1257	immune	abstract[68]|abstract|abstract[72]	new[68]|new|new[72]	coref	13-16
10-13	1258-1267	responses	abstract[68]|abstract[72]	new[68]|new[72]	_	_
10-14	1268-1270	to	abstract[68]|abstract[72]	new[68]|new[72]	_	_
10-15	1271-1276	virus	abstract[68]|abstract[72]|abstract|event[74]	new[68]|new[72]|giv|giv[74]	coref|coref|coref|coref	10-22|15-10[140_74]|10-22|15-10[140_74]
10-16	1277-1286	infection	abstract[68]|abstract[72]|event[74]	new[68]|new[72]|giv[74]	_	_
10-17	1287-1288	,	_	_	_	_
10-18	1289-1292	and	_	_	_	_
10-19	1293-1296	the	abstract[75]	new[75]	coref	14-49[127_75]
10-20	1297-1307	mechanisms	abstract[75]	new[75]	_	_
10-21	1308-1310	of	abstract[75]	new[75]	_	_
10-22	1311-1316	virus	abstract[75]|abstract|abstract[77]	new[75]|giv|new[77]	_	_
10-23	1317-1323	immune	abstract[75]|abstract[77]	new[75]|new[77]	_	_
10-24	1324-1331	evasion	abstract[75]|abstract[77]	new[75]|new[77]	_	_
10-25	1332-1334	of	abstract[75]|abstract[77]	new[75]|new[77]	_	_
10-26	1335-1342	related	abstract[75]|abstract[77]|place[80]	new[75]|new[77]|giv[80]	coref	13-14[101_80]
10-27	1343-1347	host	abstract[75]|abstract[77]|person|place[80]	new[75]|new[77]|giv|giv[80]	coref	20-10
10-28	1348-1355	defense	abstract[75]|abstract[77]|abstract|place[80]	new[75]|new[77]|giv|giv[80]	coref	20-11
10-29	1356-1364	pathways	abstract[75]|abstract[77]|place[80]	new[75]|new[77]|giv[80]	_	_
10-30	1365-1366	.	_	_	_	_

#Text=The clinical presentation of VSG-driven pathology and strategies to use VSGs to cure chronic viral infections are also discussed .
11-1	1367-1370	The	abstract[81]	new[81]	_	_
11-2	1371-1379	clinical	abstract[81]	new[81]	_	_
11-3	1380-1392	presentation	abstract[81]	new[81]	_	_
11-4	1393-1395	of	abstract[81]	new[81]	_	_
11-5	1396-1406	VSG-driven	abstract[81]|place|abstract[83]	new[81]|new|new[83]	_	_
11-6	1407-1416	pathology	abstract[81]|abstract[83]	new[81]|new[83]	_	_
11-7	1417-1420	and	abstract[81]	new[81]	_	_
11-8	1421-1431	strategies	abstract[81]|abstract	new[81]|new	_	_
11-9	1432-1434	to	_	_	_	_
11-10	1435-1438	use	_	_	_	_
11-11	1439-1443	VSGs	substance	giv	coref	12-33
11-12	1444-1446	to	_	_	_	_
11-13	1447-1451	cure	_	_	_	_
11-14	1452-1459	chronic	abstract[87]	new[87]	coref	13-31[105_0]
11-15	1460-1465	viral	object|abstract[87]	new|new[87]	coref	13-31
11-16	1466-1476	infections	abstract[87]	new[87]	_	_
11-17	1477-1480	are	_	_	_	_
11-18	1481-1485	also	_	_	_	_
11-19	1486-1495	discussed	_	_	_	_
11-20	1496-1497	.	_	_	_	_

#Text=In this special Issue , we endeavored to assemble a collection of research papers and reviews that , together , will offer a comprehensive view on new areas of research pertaining to VSGs .
12-1	1498-1500	In	_	_	_	_
12-2	1501-1505	this	abstract[88]	giv[88]	coref	23-3[238_88]
12-3	1506-1513	special	abstract[88]	giv[88]	_	_
12-4	1514-1519	Issue	abstract[88]	giv[88]	_	_
12-5	1520-1521	,	_	_	_	_
12-6	1522-1524	we	person	giv	ana	20-6
12-7	1525-1535	endeavored	_	_	_	_
12-8	1536-1538	to	_	_	_	_
12-9	1539-1547	assemble	_	_	_	_
12-10	1548-1549	a	abstract[90]	new[90]	_	_
12-11	1550-1560	collection	abstract[90]	new[90]	_	_
12-12	1561-1563	of	abstract[90]	new[90]	_	_
12-13	1564-1572	research	abstract[90]|object[91]	new[90]|new[91]	_	_
12-14	1573-1579	papers	abstract[90]|object[91]	new[90]|new[91]	_	_
12-15	1580-1583	and	abstract[90]	new[90]	_	_
12-16	1584-1591	reviews	abstract[90]|abstract	new[90]|new	_	_
12-17	1592-1596	that	_	_	_	_
12-18	1597-1598	,	_	_	_	_
12-19	1599-1607	together	_	_	_	_
12-20	1608-1609	,	_	_	_	_
12-21	1610-1614	will	_	_	_	_
12-22	1615-1620	offer	_	_	_	_
12-23	1621-1622	a	abstract[93]	new[93]	_	_
12-24	1623-1636	comprehensive	abstract[93]	new[93]	_	_
12-25	1637-1641	view	abstract[93]	new[93]	_	_
12-26	1642-1644	on	abstract[93]	new[93]	_	_
12-27	1645-1648	new	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-28	1649-1654	areas	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-29	1655-1657	of	abstract[93]|abstract[94]	new[93]|new[94]	_	_
12-30	1658-1666	research	abstract[93]|abstract[94]|abstract	new[93]|new[94]|giv	_	_
12-31	1667-1677	pertaining	_	_	_	_
12-32	1678-1680	to	_	_	_	_
12-33	1681-1685	VSGs	abstract	giv	coref	13-26[103_0]
12-34	1686-1687	.	_	_	_	_

#Text=Majzoub et al. contributed an exciting review , addressing the current knowledge of the innate immune pathways involved in sensing , signaling , and inducing ISGs and VSGs to counter viral infections .
13-1	1688-1695	Majzoub	person	new	_	_
13-2	1696-1698	et	_	_	_	_
13-3	1699-1702	al.	_	_	_	_
13-4	1703-1714	contributed	_	_	_	_
13-5	1715-1717	an	abstract[98]	new[98]	_	_
13-6	1718-1726	exciting	abstract[98]	new[98]	_	_
13-7	1727-1733	review	abstract[98]	new[98]	_	_
13-8	1734-1735	,	_	_	_	_
13-9	1736-1746	addressing	_	_	_	_
13-10	1747-1750	the	abstract[99]	new[99]	_	_
13-11	1751-1758	current	abstract[99]	new[99]	_	_
13-12	1759-1768	knowledge	abstract[99]	new[99]	_	_
13-13	1769-1771	of	abstract[99]	new[99]	_	_
13-14	1772-1775	the	abstract[99]|place[101]	new[99]|giv[101]	coref	14-37[122_101]
13-15	1776-1782	innate	abstract[99]|place[101]	new[99]|giv[101]	_	_
13-16	1783-1789	immune	abstract[99]|abstract|place[101]	new[99]|giv|giv[101]	coref	15-17
13-17	1790-1798	pathways	abstract[99]|place[101]	new[99]|giv[101]	_	_
13-18	1799-1807	involved	_	_	_	_
13-19	1808-1810	in	_	_	_	_
13-20	1811-1818	sensing	abstract	new	_	_
13-21	1819-1820	,	_	_	_	_
13-22	1821-1830	signaling	_	_	_	_
13-23	1831-1832	,	_	_	_	_
13-24	1833-1836	and	_	_	_	_
13-25	1837-1845	inducing	_	_	_	_
13-26	1846-1850	ISGs	abstract[103]	giv[103]	ana	14-1[0_103]
13-27	1851-1854	and	abstract[103]	giv[103]	_	_
13-28	1855-1859	VSGs	abstract[103]	giv[103]	_	_
13-29	1860-1862	to	_	_	_	_
13-30	1863-1870	counter	_	_	_	_
13-31	1871-1876	viral	object|abstract[105]	giv|giv[105]	coref|coref|coref|coref	14-42|14-42[125_105]|14-42|14-42[125_105]
13-32	1877-1887	infections	abstract[105]	giv[105]	_	_
13-33	1888-1889	.	_	_	_	_

#Text=Their manuscript specifically discussed Toll-like receptors ( TLRs ) , RIG-I-like receptors ( RLRs ) , and the cGAS-STING pathway , placing their evolution into perspective in diverse organisms and the dynamic co-evolution and diversification of these pathways with respect to viral infections . Liu et al. discussed the mechanisms underlying how herpesviruses can be detected by pattern recognition receptors ( PRRs ) to induce the expression of interferons ( IFNs ) and inflammatory cytokines .
14-1	1890-1895	Their	abstract|object[107]	giv|new[107]	ana|ana	14-23|14-23
14-2	1896-1906	manuscript	object[107]	new[107]	_	_
14-3	1907-1919	specifically	_	_	_	_
14-4	1920-1929	discussed	_	_	_	_
14-5	1930-1939	Toll-like	abstract|substance[109]	new|new[109]	_	_
14-6	1940-1949	receptors	substance[109]	new[109]	_	_
14-7	1950-1951	(	_	_	_	_
14-8	1952-1956	TLRs	abstract	new	_	_
14-9	1957-1958	)	_	_	_	_
14-10	1959-1960	,	_	_	_	_
14-11	1961-1971	RIG-I-like	abstract|substance[112]	new|new[112]	coref|coref	14-58[131_112]|14-58[131_112]
14-12	1972-1981	receptors	substance[112]	new[112]	_	_
14-13	1982-1983	(	_	_	_	_
14-14	1984-1988	RLRs	abstract	new	_	_
14-15	1989-1990	)	_	_	_	_
14-16	1991-1992	,	_	_	_	_
14-17	1993-1996	and	_	_	_	_
14-18	1997-2000	the	abstract[115]	new[115]	_	_
14-19	2001-2011	cGAS-STING	abstract|abstract[115]	new|new[115]	_	_
14-20	2012-2019	pathway	abstract[115]	new[115]	_	_
14-21	2020-2021	,	_	_	_	_
14-22	2022-2029	placing	_	_	_	_
14-23	2030-2035	their	abstract|abstract[117]	giv|new[117]	coref|coref	15-20[144_0]|15-20[144_0]
14-24	2036-2045	evolution	abstract[117]	new[117]	_	_
14-25	2046-2050	into	_	_	_	_
14-26	2051-2062	perspective	abstract[118]	new[118]	_	_
14-27	2063-2065	in	abstract[118]	new[118]	_	_
14-28	2066-2073	diverse	abstract[118]|abstract[119]	new[118]|new[119]	_	_
14-29	2074-2083	organisms	abstract[118]|abstract[119]	new[118]|new[119]	_	_
14-30	2084-2087	and	abstract[118]	new[118]	_	_
14-31	2088-2091	the	abstract[118]|abstract[120]	new[118]|new[120]	_	_
14-32	2092-2099	dynamic	abstract[118]|abstract[120]	new[118]|new[120]	_	_
14-33	2100-2112	co-evolution	abstract[118]|abstract[120]	new[118]|new[120]	_	_
14-34	2113-2116	and	abstract[118]	new[118]	_	_
14-35	2117-2132	diversification	abstract[118]|abstract[121]	new[118]|new[121]	_	_
14-36	2133-2135	of	abstract[118]|abstract[121]	new[118]|new[121]	_	_
14-37	2136-2141	these	abstract[118]|abstract[121]|place[122]	new[118]|new[121]|giv[122]	coref	16-8[162_122]
14-38	2142-2150	pathways	abstract[118]|abstract[121]|place[122]	new[118]|new[121]|giv[122]	_	_
14-39	2151-2155	with	abstract[118]|abstract[121]|place[122]	new[118]|new[121]|giv[122]	_	_
14-40	2156-2163	respect	abstract[118]|abstract[121]|place[122]|abstract[123]	new[118]|new[121]|giv[122]|new[123]	coref	15-43[152_123]
14-41	2164-2166	to	abstract[118]|abstract[121]|place[122]|abstract[123]	new[118]|new[121]|giv[122]|new[123]	_	_
14-42	2167-2172	viral	abstract[118]|abstract[121]|place[122]|abstract[123]|object|abstract[125]	new[118]|new[121]|giv[122]|new[123]|giv|giv[125]	_	_
14-43	2173-2183	infections	abstract[118]|abstract[121]|place[122]|abstract[123]|abstract[125]	new[118]|new[121]|giv[122]|new[123]|giv[125]	_	_
14-44	2184-2185	.	_	_	_	_
14-45	2186-2189	Liu	person	new	_	_
14-46	2190-2192	et	_	_	_	_
14-47	2193-2196	al.	_	_	_	_
14-48	2197-2206	discussed	_	_	_	_
14-49	2207-2210	the	abstract[127]	giv[127]	_	_
14-50	2211-2221	mechanisms	abstract[127]	giv[127]	_	_
14-51	2222-2232	underlying	_	_	_	_
14-52	2233-2236	how	_	_	_	_
14-53	2237-2250	herpesviruses	person	new	ana	15-1
14-54	2251-2254	can	_	_	_	_
14-55	2255-2257	be	_	_	_	_
14-56	2258-2266	detected	_	_	_	_
14-57	2267-2269	by	_	_	_	_
14-58	2270-2277	pattern	abstract|abstract[131]	new|giv[131]	appos|appos	14-62[0_131]|14-62[0_131]
14-59	2278-2289	recognition	abstract|abstract[131]	new|giv[131]	_	_
14-60	2290-2299	receptors	abstract[131]	giv[131]	_	_
14-61	2300-2301	(	_	_	_	_
14-62	2302-2306	PRRs	abstract	giv	_	_
14-63	2307-2308	)	_	_	_	_
14-64	2309-2311	to	_	_	_	_
14-65	2312-2318	induce	_	_	_	_
14-66	2319-2322	the	abstract[133]	new[133]	coref	16-15[163_133]
14-67	2323-2333	expression	abstract[133]	new[133]	_	_
14-68	2334-2336	of	abstract[133]	new[133]	_	_
14-69	2337-2348	interferons	abstract[133]|abstract	new[133]|new	appos	14-71
14-70	2349-2350	(	_	_	_	_
14-71	2351-2355	IFNs	abstract	giv	_	_
14-72	2356-2357	)	_	_	_	_
14-73	2358-2361	and	_	_	_	_
14-74	2362-2374	inflammatory	abstract[136]	new[136]	_	_
14-75	2375-2384	cytokines	abstract[136]	new[136]	_	_
14-76	2385-2386	.	_	_	_	_

#Text=They also described the ability of herpesviruses to establish persistent infection in the presence of active immune responses involving VSGs . Asmi et al. reviewed Small Ubiquitin-like Modifier ( SUMO ) protein conjugation as a component of intrinsic and innate immunity , specifically with respect to rhabdoviruses infection and in relation to the production and secretion of interferon .
15-1	2387-2391	They	person	giv	coref	15-7
15-2	2392-2396	also	_	_	_	_
15-3	2397-2406	described	_	_	_	_
15-4	2407-2410	the	abstract[138]	new[138]	_	_
15-5	2411-2418	ability	abstract[138]	new[138]	_	_
15-6	2419-2421	of	abstract[138]	new[138]	_	_
15-7	2422-2435	herpesviruses	abstract[138]|animal	new[138]|giv	_	_
15-8	2436-2438	to	_	_	_	_
15-9	2439-2448	establish	_	_	_	_
15-10	2449-2459	persistent	event[140]	giv[140]	coref	15-47[154_140]
15-11	2460-2469	infection	event[140]	giv[140]	_	_
15-12	2470-2472	in	event[140]	giv[140]	_	_
15-13	2473-2476	the	event[140]|abstract[141]	giv[140]|new[141]	_	_
15-14	2477-2485	presence	event[140]|abstract[141]	giv[140]|new[141]	_	_
15-15	2486-2488	of	event[140]|abstract[141]	giv[140]|new[141]	_	_
15-16	2489-2495	active	event[140]|abstract[141]|abstract[143]	giv[140]|new[141]|giv[143]	coref	20-9[222_143]
15-17	2496-2502	immune	event[140]|abstract[141]|abstract|abstract[143]	giv[140]|new[141]|giv|giv[143]	_	_
15-18	2503-2512	responses	event[140]|abstract[141]|abstract[143]	giv[140]|new[141]|giv[143]	_	_
15-19	2513-2522	involving	_	_	_	_
15-20	2523-2527	VSGs	abstract[144]	giv[144]	coref	16-53[175_144]
15-21	2528-2529	.	abstract[144]	giv[144]	_	_
15-22	2530-2534	Asmi	abstract[144]|person	giv[144]|new	_	_
15-23	2535-2537	et	abstract[144]	giv[144]	_	_
15-24	2538-2541	al.	abstract[144]	giv[144]	_	_
15-25	2542-2550	reviewed	_	_	_	_
15-26	2551-2556	Small	abstract[147]	new[147]	appos	15-30[0_147]
15-27	2557-2571	Ubiquitin-like	abstract|abstract[147]	new|new[147]	_	_
15-28	2572-2580	Modifier	abstract[147]	new[147]	_	_
15-29	2581-2582	(	_	_	_	_
15-30	2583-2587	SUMO	abstract	giv	appos	15-32[150_0]
15-31	2588-2589	)	_	_	_	_
15-32	2590-2597	protein	substance|abstract[150]	new|giv[150]	_	_
15-33	2598-2609	conjugation	abstract[150]	giv[150]	_	_
15-34	2610-2612	as	abstract[150]	giv[150]	_	_
15-35	2613-2614	a	abstract[150]	giv[150]	_	_
15-36	2615-2624	component	abstract[150]	giv[150]	_	_
15-37	2625-2627	of	abstract[150]	giv[150]	_	_
15-38	2628-2637	intrinsic	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
15-39	2638-2641	and	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
15-40	2642-2648	innate	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
15-41	2649-2657	immunity	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
15-42	2658-2659	,	abstract[150]	giv[150]	_	_
15-43	2660-2672	specifically	abstract[150]|abstract[152]	giv[150]|giv[152]	coref	20-22[223_152]
15-44	2673-2677	with	abstract[150]|abstract[152]	giv[150]|giv[152]	_	_
15-45	2678-2685	respect	abstract[150]|abstract[152]	giv[150]|giv[152]	_	_
15-46	2686-2688	to	abstract[150]|abstract[152]	giv[150]|giv[152]	_	_
15-47	2689-2702	rhabdoviruses	abstract[150]|abstract[152]|object|event[154]	giv[150]|giv[152]|new|giv[154]	coref|coref	16-66[0_154]|16-66[0_154]
15-48	2703-2712	infection	abstract[150]|abstract[152]|event[154]	giv[150]|giv[152]|giv[154]	_	_
15-49	2713-2716	and	_	_	_	_
15-50	2717-2719	in	_	_	_	_
15-51	2720-2728	relation	abstract[155]	new[155]	_	_
15-52	2729-2731	to	abstract[155]	new[155]	_	_
15-53	2732-2735	the	abstract[155]|abstract[156]	new[155]|new[156]	coref	16-1[160_156]
15-54	2736-2746	production	abstract[155]|abstract[156]	new[155]|new[156]	_	_
15-55	2747-2750	and	abstract[155]	new[155]	_	_
15-56	2751-2760	secretion	abstract[155]|abstract[157]	new[155]|new[157]	_	_
15-57	2761-2763	of	abstract[155]|abstract[157]	new[155]|new[157]	_	_
15-58	2764-2774	interferon	abstract[155]|abstract[157]|organization	new[155]|new[157]|giv	coref	16-2
15-59	2775-2776	.	_	_	_	_

#Text=Rhabdoviruses-induced interferon production and the activation of interferon signaling pathways , as well as the expression and functions of viral restriction factors , are discussed . Ashley et al. reported that by using cells engineered to block either the response to , or production of , type-I IFN , the regulation of IFN-independent ISGs was examined in the context of human cytomegalovirus ( HCMV ) infection .
16-1	2777-2798	Rhabdoviruses-induced	abstract[160]	giv[160]	coref	16-44[170_160]
16-2	2799-2809	interferon	organization|abstract[160]	giv|giv[160]	_	_
16-3	2810-2820	production	abstract[160]	giv[160]	_	_
16-4	2821-2824	and	_	_	_	_
16-5	2825-2828	the	event[161]	new[161]	coref	18-31[205_161]
16-6	2829-2839	activation	event[161]	new[161]	_	_
16-7	2840-2842	of	event[161]	new[161]	_	_
16-8	2843-2853	interferon	event[161]|place[162]	new[161]|giv[162]	_	_
16-9	2854-2863	signaling	event[161]|place[162]	new[161]|giv[162]	_	_
16-10	2864-2872	pathways	event[161]|place[162]	new[161]|giv[162]	_	_
16-11	2873-2874	,	_	_	_	_
16-12	2875-2877	as	_	_	_	_
16-13	2878-2882	well	_	_	_	_
16-14	2883-2885	as	_	_	_	_
16-15	2886-2889	the	abstract[163]	giv[163]	coref	18-18[200_163]
16-16	2890-2900	expression	abstract[163]	giv[163]	_	_
16-17	2901-2904	and	_	_	_	_
16-18	2905-2914	functions	abstract[164]	new[164]	_	_
16-19	2915-2917	of	abstract[164]	new[164]	_	_
16-20	2918-2923	viral	abstract[164]|abstract[166]	new[164]|new[166]	_	_
16-21	2924-2935	restriction	abstract[164]|abstract|abstract[166]	new[164]|new|new[166]	_	_
16-22	2936-2943	factors	abstract[164]|abstract[166]	new[164]|new[166]	_	_
16-23	2944-2945	,	_	_	_	_
16-24	2946-2949	are	_	_	_	_
16-25	2950-2959	discussed	_	_	_	_
16-26	2960-2961	.	_	_	_	_
16-27	2962-2968	Ashley	person	new	ana	19-3
16-28	2969-2971	et	_	_	_	_
16-29	2972-2975	al.	_	_	_	_
16-30	2976-2984	reported	_	_	_	_
16-31	2985-2989	that	_	_	_	_
16-32	2990-2992	by	_	_	_	_
16-33	2993-2998	using	_	_	_	_
16-34	2999-3004	cells	object	giv	_	_
16-35	3005-3015	engineered	_	_	_	_
16-36	3016-3018	to	_	_	_	_
16-37	3019-3024	block	_	_	_	_
16-38	3025-3031	either	abstract[169]	new[169]	_	_
16-39	3032-3035	the	abstract[169]	new[169]	_	_
16-40	3036-3044	response	abstract[169]	new[169]	_	_
16-41	3045-3047	to	_	_	_	_
16-42	3048-3049	,	_	_	_	_
16-43	3050-3052	or	_	_	_	_
16-44	3053-3063	production	abstract[170]	giv[170]	coref	19-19[211_170]
16-45	3064-3066	of	abstract[170]	giv[170]	_	_
16-46	3067-3068	,	abstract[170]	giv[170]	_	_
16-47	3069-3075	type-I	abstract[170]|abstract|abstract[172]	giv[170]|new|giv[172]	coref|coref|coref|coref	17-30|17-30[192_172]|17-30|17-30[192_172]
16-48	3076-3079	IFN	abstract[170]|abstract[172]	giv[170]|giv[172]	_	_
16-49	3080-3081	,	_	_	_	_
16-50	3082-3085	the	abstract[173]	new[173]	_	_
16-51	3086-3096	regulation	abstract[173]	new[173]	_	_
16-52	3097-3099	of	abstract[173]	new[173]	_	_
16-53	3100-3115	IFN-independent	abstract[173]|person|abstract[175]	new[173]|new|giv[175]	coref|coref|coref|coref	17-1[180_175]|18-15|17-1[180_175]|18-15
16-54	3116-3120	ISGs	abstract[173]|abstract[175]	new[173]|giv[175]	_	_
16-55	3121-3124	was	_	_	_	_
16-56	3125-3133	examined	_	_	_	_
16-57	3134-3136	in	_	_	_	_
16-58	3137-3140	the	abstract[176]	new[176]	_	_
16-59	3141-3148	context	abstract[176]	new[176]	_	_
16-60	3149-3151	of	abstract[176]	new[176]	_	_
16-61	3152-3157	human	abstract[176]|abstract[177]	new[176]|new[177]	appos	16-64[0_177]
16-62	3158-3173	cytomegalovirus	abstract[176]|abstract[177]	new[176]|new[177]	_	_
16-63	3174-3175	(	abstract[176]	new[176]	_	_
16-64	3176-3180	HCMV	abstract[176]|abstract	new[176]|giv	coref	17-26
16-65	3181-3182	)	abstract[176]	new[176]	_	_
16-66	3183-3192	infection	abstract[176]|event	new[176]|giv	_	_
16-67	3193-3194	.	_	_	_	_

#Text=Several ISGs , including IFIT1 , IFIT2 , IFIT3 , Mx1 , Mx2 , CXCL10 , and ISG15 were found to be upregulated transcriptionally following HCMV infection independently of type-I IFN .
17-1	3195-3202	Several	abstract[180]	giv[180]	coref	21-16[231_180]
17-2	3203-3207	ISGs	abstract[180]	giv[180]	_	_
17-3	3208-3209	,	abstract[180]	giv[180]	_	_
17-4	3210-3219	including	abstract[180]	giv[180]	_	_
17-5	3220-3225	IFIT1	abstract[180]|abstract|abstract[182]	giv[180]|new|new[182]	ana|ana	18-10[0_182]|18-10[0_182]
17-6	3226-3227	,	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
17-7	3228-3233	IFIT2	abstract[180]|abstract[182]|abstract	giv[180]|new[182]|new	_	_
17-8	3234-3235	,	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
17-9	3236-3241	IFIT3	abstract[180]|abstract[182]|abstract	giv[180]|new[182]|new	_	_
17-10	3242-3243	,	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
17-11	3244-3247	Mx1	abstract[180]|abstract[182]|abstract	giv[180]|new[182]|new	_	_
17-12	3248-3249	,	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
17-13	3250-3253	Mx2	abstract[180]|abstract[182]|abstract	giv[180]|new[182]|new	_	_
17-14	3254-3255	,	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
17-15	3256-3262	CXCL10	abstract[180]|abstract[182]|time	giv[180]|new[182]|new	_	_
17-16	3263-3264	,	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
17-17	3265-3268	and	abstract[180]|abstract[182]	giv[180]|new[182]	_	_
17-18	3269-3274	ISG15	abstract[180]|abstract[182]|abstract	giv[180]|new[182]|new	_	_
17-19	3275-3279	were	_	_	_	_
17-20	3280-3285	found	_	_	_	_
17-21	3286-3288	to	_	_	_	_
17-22	3289-3291	be	_	_	_	_
17-23	3292-3303	upregulated	_	_	_	_
17-24	3304-3321	transcriptionally	_	_	_	_
17-25	3322-3331	following	event[190]	new[190]	_	_
17-26	3332-3336	HCMV	object|event[190]	giv|new[190]	coref	18-21
17-27	3337-3346	infection	event[190]	new[190]	_	_
17-28	3347-3360	independently	event[190]	new[190]	_	_
17-29	3361-3363	of	event[190]	new[190]	_	_
17-30	3364-3370	type-I	event[190]|abstract|abstract[192]	new[190]|giv|giv[192]	coref|coref	19-20[0_192]|19-20[0_192]
17-31	3371-3374	IFN	event[190]|abstract[192]	new[190]|giv[192]	_	_
17-32	3375-3376	.	_	_	_	_

#Text=Furthermore , by using IRF3 knockdown CRISPR/Cas-9 clones , they were able to demonstrate IFN-independent control of ISG expression during HCMV infection of human fibroblasts that is absolutely dependent on IRF3 activation .
18-1	3377-3388	Furthermore	_	_	_	_
18-2	3389-3390	,	_	_	_	_
18-3	3391-3393	by	_	_	_	_
18-4	3394-3399	using	_	_	_	_
18-5	3400-3404	IRF3	abstract	giv	coref	18-31
18-6	3405-3414	knockdown	_	_	_	_
18-7	3415-3427	CRISPR/Cas-9	abstract|object[195]	new|new[195]	_	_
18-8	3428-3434	clones	object[195]	new[195]	_	_
18-9	3435-3436	,	_	_	_	_
18-10	3437-3441	they	abstract	giv	_	_
18-11	3442-3446	were	_	_	_	_
18-12	3447-3451	able	_	_	_	_
18-13	3452-3454	to	_	_	_	_
18-14	3455-3466	demonstrate	_	_	_	_
18-15	3467-3482	IFN-independent	person|abstract[198]	giv|new[198]	_	_
18-16	3483-3490	control	abstract[198]	new[198]	_	_
18-17	3491-3493	of	abstract[198]	new[198]	_	_
18-18	3494-3497	ISG	abstract[198]|person|abstract[200]	new[198]|new|giv[200]	_	_
18-19	3498-3508	expression	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
18-20	3509-3515	during	_	_	_	_
18-21	3516-3520	HCMV	object|event[202]	giv|new[202]	_	_
18-22	3521-3530	infection	event[202]	new[202]	_	_
18-23	3531-3533	of	event[202]	new[202]	_	_
18-24	3534-3539	human	event[202]|object[203]	new[202]|new[203]	_	_
18-25	3540-3551	fibroblasts	event[202]|object[203]	new[202]|new[203]	_	_
18-26	3552-3556	that	_	_	_	_
18-27	3557-3559	is	_	_	_	_
18-28	3560-3570	absolutely	_	_	_	_
18-29	3571-3580	dependent	_	_	_	_
18-30	3581-3583	on	_	_	_	_
18-31	3584-3588	IRF3	abstract|event[205]	giv|giv[205]	coref|coref|coref|coref	19-30|19-30[216_205]|19-30|19-30[216_205]
18-32	3589-3599	activation	event[205]	giv[205]	_	_
18-33	3600-3601	.	_	_	_	_

#Text=Finally , He et al. revealed that the THO complex subunit 7 homolog ( THOC7 ) negatively regulates type-I IFN production by promoting TBK1 proteasomal degradation that subsequently decreases IRF3 activation .
19-1	3602-3609	Finally	_	_	_	_
19-2	3610-3611	,	_	_	_	_
19-3	3612-3614	He	person	giv	_	_
19-4	3615-3617	et	_	_	_	_
19-5	3618-3621	al.	_	_	_	_
19-6	3622-3630	revealed	_	_	_	_
19-7	3631-3635	that	_	_	_	_
19-8	3636-3639	the	abstract[208]	new[208]	_	_
19-9	3640-3643	THO	abstract|abstract[208]	new|new[208]	_	_
19-10	3644-3651	complex	abstract[208]	new[208]	_	_
19-11	3652-3659	subunit	abstract[208]	new[208]	_	_
19-12	3660-3661	7	_	_	_	_
19-13	3662-3669	homolog	_	_	_	_
19-14	3670-3671	(	_	_	_	_
19-15	3672-3677	THOC7	abstract	new	_	_
19-16	3678-3679	)	_	_	_	_
19-17	3680-3690	negatively	_	_	_	_
19-18	3691-3700	regulates	_	_	_	_
19-19	3701-3707	type-I	abstract[211]	giv[211]	_	_
19-20	3708-3711	IFN	abstract|abstract[211]	giv|giv[211]	coref	21-3
19-21	3712-3722	production	abstract[211]	giv[211]	_	_
19-22	3723-3725	by	_	_	_	_
19-23	3726-3735	promoting	_	_	_	_
19-24	3736-3740	TBK1	abstract|event[214]	new|new[214]	_	_
19-25	3741-3752	proteasomal	animal|event[214]	new|new[214]	_	_
19-26	3753-3764	degradation	event[214]	new[214]	_	_
19-27	3765-3769	that	_	_	_	_
19-28	3770-3782	subsequently	_	_	_	_
19-29	3783-3792	decreases	_	_	_	_
19-30	3793-3797	IRF3	abstract|event[216]	giv|giv[216]	_	_
19-31	3798-3808	activation	event[216]	giv[216]	_	_
19-32	3809-3810	.	_	_	_	_

#Text=Despite the recent progress in our understanding of these host defense responses , much more is left to be unraveled with respect to the regulation of antiviral responses triggered by distinct viral species .
20-1	3811-3818	Despite	_	_	_	_
20-2	3819-3822	the	abstract[217]	new[217]	_	_
20-3	3823-3829	recent	abstract[217]	new[217]	_	_
20-4	3830-3838	progress	abstract[217]	new[217]	_	_
20-5	3839-3841	in	abstract[217]	new[217]	_	_
20-6	3842-3845	our	abstract[217]|person|abstract[219]	new[217]|giv|new[219]	ana|ana	23-1|23-1
20-7	3846-3859	understanding	abstract[217]|abstract[219]	new[217]|new[219]	_	_
20-8	3860-3862	of	abstract[217]|abstract[219]	new[217]|new[219]	_	_
20-9	3863-3868	these	abstract[217]|abstract[219]|abstract[222]	new[217]|new[219]|giv[222]	coref	20-27[225_222]
20-10	3869-3873	host	abstract[217]|abstract[219]|person|abstract[222]	new[217]|new[219]|giv|giv[222]	_	_
20-11	3874-3881	defense	abstract[217]|abstract[219]|abstract|abstract[222]	new[217]|new[219]|giv|giv[222]	coref	21-10
20-12	3882-3891	responses	abstract[217]|abstract[219]|abstract[222]	new[217]|new[219]|giv[222]	_	_
20-13	3892-3893	,	_	_	_	_
20-14	3894-3898	much	_	_	_	_
20-15	3899-3903	more	_	_	_	_
20-16	3904-3906	is	_	_	_	_
20-17	3907-3911	left	_	_	_	_
20-18	3912-3914	to	_	_	_	_
20-19	3915-3917	be	_	_	_	_
20-20	3918-3927	unraveled	_	_	_	_
20-21	3928-3932	with	_	_	_	_
20-22	3933-3940	respect	abstract[223]	giv[223]	_	_
20-23	3941-3943	to	abstract[223]	giv[223]	_	_
20-24	3944-3947	the	abstract[223]|abstract[224]	giv[223]|new[224]	_	_
20-25	3948-3958	regulation	abstract[223]|abstract[224]	giv[223]|new[224]	_	_
20-26	3959-3961	of	abstract[223]|abstract[224]	giv[223]|new[224]	_	_
20-27	3962-3971	antiviral	abstract[223]|abstract[224]|abstract[225]	giv[223]|new[224]|giv[225]	coref	21-9[230_225]
20-28	3972-3981	responses	abstract[223]|abstract[224]|abstract[225]	giv[223]|new[224]|giv[225]	_	_
20-29	3982-3991	triggered	_	_	_	_
20-30	3992-3994	by	_	_	_	_
20-31	3995-4003	distinct	abstract[226]	new[226]	_	_
20-32	4004-4009	viral	abstract[226]	new[226]	_	_
20-33	4010-4017	species	abstract[226]	new[226]	_	_
20-34	4018-4019	.	_	_	_	_

#Text=Clearly , IFN is a major component of host defense responses , but there are many ISGs whose antiviral activities remain to be clarified that can be regulated independently of IFN .
21-1	4020-4027	Clearly	_	_	_	_
21-2	4028-4029	,	_	_	_	_
21-3	4030-4033	IFN	abstract	giv	coref	21-5[228_0]
21-4	4034-4036	is	_	_	_	_
21-5	4037-4038	a	abstract[228]	giv[228]	coref	21-31[0_228]
21-6	4039-4044	major	abstract[228]	giv[228]	_	_
21-7	4045-4054	component	abstract[228]	giv[228]	_	_
21-8	4055-4057	of	abstract[228]	giv[228]	_	_
21-9	4058-4062	host	abstract[228]|abstract[230]	giv[228]|giv[230]	_	_
21-10	4063-4070	defense	abstract[228]|abstract|abstract[230]	giv[228]|giv|giv[230]	_	_
21-11	4071-4080	responses	abstract[228]|abstract[230]	giv[228]|giv[230]	_	_
21-12	4081-4082	,	_	_	_	_
21-13	4083-4086	but	_	_	_	_
21-14	4087-4092	there	_	_	_	_
21-15	4093-4096	are	_	_	_	_
21-16	4097-4101	many	abstract[231]	giv[231]	coref	22-1[234_231]
21-17	4102-4106	ISGs	abstract[231]	giv[231]	_	_
21-18	4107-4112	whose	abstract[232]	giv[232]	_	_
21-19	4113-4122	antiviral	abstract[232]	giv[232]	_	_
21-20	4123-4133	activities	abstract[232]	giv[232]	_	_
21-21	4134-4140	remain	_	_	_	_
21-22	4141-4143	to	_	_	_	_
21-23	4144-4146	be	_	_	_	_
21-24	4147-4156	clarified	_	_	_	_
21-25	4157-4161	that	_	_	_	_
21-26	4162-4165	can	_	_	_	_
21-27	4166-4168	be	_	_	_	_
21-28	4169-4178	regulated	_	_	_	_
21-29	4179-4192	independently	_	_	_	_
21-30	4193-4195	of	_	_	_	_
21-31	4196-4199	IFN	abstract	giv	coref	23-25
21-32	4200-4201	.	_	_	_	_

#Text=These new genes would likely be ideal candidates to be targeted through therapeutic intervention as novel antiviral strategies .
22-1	4202-4207	These	person[234]	giv[234]	coref	22-7[235_234]
22-2	4208-4211	new	person[234]	giv[234]	_	_
22-3	4212-4217	genes	person[234]	giv[234]	_	_
22-4	4218-4223	would	_	_	_	_
22-5	4224-4230	likely	_	_	_	_
22-6	4231-4233	be	_	_	_	_
22-7	4234-4239	ideal	person[235]	giv[235]	coref	23-19[0_235]
22-8	4240-4250	candidates	person[235]	giv[235]	_	_
22-9	4251-4253	to	_	_	_	_
22-10	4254-4256	be	_	_	_	_
22-11	4257-4265	targeted	_	_	_	_
22-12	4266-4273	through	_	_	_	_
22-13	4274-4285	therapeutic	event[236]	new[236]	_	_
22-14	4286-4298	intervention	event[236]	new[236]	_	_
22-15	4299-4301	as	_	_	_	_
22-16	4302-4307	novel	_	_	_	_
22-17	4308-4317	antiviral	_	_	_	_
22-18	4318-4328	strategies	_	_	_	_
22-19	4329-4330	.	_	_	_	_

#Text=We hope this special issue provides a wealth of basic scientific data and introduces new concepts pertaining to ISGs that are regulated independently of IFN signaling .
23-1	4331-4333	We	person	giv	_	_
23-2	4334-4338	hope	_	_	_	_
23-3	4339-4343	this	abstract[238]	giv[238]	_	_
23-4	4344-4351	special	abstract[238]	giv[238]	_	_
23-5	4352-4357	issue	abstract[238]	giv[238]	_	_
23-6	4358-4366	provides	_	_	_	_
23-7	4367-4368	a	abstract[239]	new[239]	_	_
23-8	4369-4375	wealth	abstract[239]	new[239]	_	_
23-9	4376-4378	of	abstract[239]	new[239]	_	_
23-10	4379-4384	basic	abstract[239]|abstract[240]	new[239]|new[240]	_	_
23-11	4385-4395	scientific	abstract[239]|abstract[240]	new[239]|new[240]	_	_
23-12	4396-4400	data	abstract[239]|abstract[240]	new[239]|new[240]	_	_
23-13	4401-4404	and	_	_	_	_
23-14	4405-4415	introduces	_	_	_	_
23-15	4416-4419	new	abstract[241]	new[241]	_	_
23-16	4420-4428	concepts	abstract[241]	new[241]	_	_
23-17	4429-4439	pertaining	_	_	_	_
23-18	4440-4442	to	_	_	_	_
23-19	4443-4447	ISGs	abstract	giv	_	_
23-20	4448-4452	that	_	_	_	_
23-21	4453-4456	are	_	_	_	_
23-22	4457-4466	regulated	_	_	_	_
23-23	4467-4480	independently	_	_	_	_
23-24	4481-4483	of	_	_	_	_
23-25	4484-4487	IFN	abstract|abstract[244]	giv|new[244]	_	_
23-26	4488-4497	signaling	abstract[244]	new[244]	_	_
23-27	4498-4499	.	_	_	_	_
